

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



上海復旦張江生物醫藥股份有限公司

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code:1349)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT 2025

Reference is made to the 2025 annual report of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.* (the “**Company**”) dated 29 April 2026 (the “**2025 Annual Report**”). Unless otherwise specified, capitalised terms used in this announcement shall have the same meanings as those defined in the 2025 Annual Report.

Pursuant to Rule 14A.72 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”), the Company would like to clarify that save for the related party transactions set out in the paragraph headed “Sales of goods” disclosed in Note 8(5)(b) to the Notes to the Consolidated Financial Statements on page 258 of the 2025 Annual Report (the “**Transactions**”) which constituted continuing connected transactions, no other related party transactions as disclosed under Note 8 to the Notes to the Consolidated Financial Statements of the 2025 Annual Report constitutes connected transactions or continuing connected transactions that are subject to announcement, circular or shareholders’ approval requirements under Chapter 14A of the Listing Rules.

The Company further confirms that it has complied with the requirements in accordance with Chapter 14A of the Listing Rules in respect of the Transactions.

Save as disclosed above, all other information contained in the 2025 Annual Report remains unchanged. This announcement is supplemental to and should be read in conjunction with the 2025 Annual Report.

By order of the Board
Zhao Da Jun
Chairman

As at the date on the publication of this announcement, the Board comprises:

Mr. Zhao Da Jun (Executive Director)

Ms. Xue Yan (Executive Director)

Mr. Zhong Tao (Non-executive Director)

Ms. Yu Xiao Yang (Non-executive Director)

Mr. Wang Hong Guang (Independent Non-executive Director)

Mr. Lam Siu Wing (Independent Non-executive Director)

Mr. Xu Pei Long (Independent Non-executive Director)

Ms. Qu Ya Nan (Employee Director)

Shanghai, the PRC

24 September 2026

** For identification purpose only*